Abstract: The present invention relates to monoclonal antibodies of class IgG1 and IgM possessing among others the property to bind to stable heteroduplex cruciform DNA structures constructed from two DNA plasmids, to the hybrid cell lines producing such antibodies, to a method for producing the cell lines and to a method for enhancing DNA replication in a cell system containing cruciforms functioning as signals for the initiation of DNA replication.

Abstract: A human IgG.sub.1 type monoclonal antibody which possesses a molecular weight in the range of 180,000.+-.20,000 as measured by the method of polyacrylamide gel electrophoresis performed in the presence of sodium dodecyl sulfate and is specific to nicotinic acetylcholine receptor. The human IgG.sub.1 type monoclonal antibody mentioned above is produced by a method which comprises fusing human cells capable of producing an antibody against nicotinic acetylcholine receptor with propagable human cells thereby giving rise to a hybridoma capable of producing the aforementioned human IgG.sub.1 type monoclonal antibody, selecting the hybridoma from the production of the fusion, culturing the hybridoma thereby giving rise to the aforementioned human IgG.sub.1 type monoclonal antibody, and selecting the antibody from the cultured medium. The hybridoma mentioned above is also identified.

Abstract: Monoclonal antibodies specific for an epitope found on hemoglobin glycated both in vivo and in vitro but not found on hemoglobin A.sub.o or hemoglobin A.sub.1c are provided. Use of these antibodies to measure glycohemoglobin levels in the blood provides a measure of the glucose levels in the erythrocyte for the previous 90-120 days. No reduction of the blood sample is required to produce the epitope recognized by the monoclonal antibodies.

Abstract: Four monoclonal antibodies are found which selectively identify prostate cancer. These monoclonals are therefore useful in diagnosis and differential diagnosis of prostate cancer.

Abstract: Hybridoma cell lines that produce monoclonal antibodies that differentially recognize glycolipids with mono-, di-, and trifucosylated type 2 chain structures are disclosed. The monoclonal antibodies can be used to detect specific types of tumor cells that are characterized by enrichment in mono-, di-, or trifucosylated type 2 chain structure. As such, the antibodies produced by the hybridoma cell lines are useful for diagnosis and treatment of human cancer. Also disclosed is an improved method of raising hybridoma cell lines by selecting the hybridomas by positive reactively with one or more fucosylated type 2 chain structures selected from the group consisting of III.sup.3 FucnLc.sub.4, V.sup.3 FucnLc.sub.6, III.sup.3 FucnLc.sub.6, III.sup.3 V.sup.3 Fuc.sub.2 nLc.sub.6, and III.sup.3 V.sup.3 VII.sup.3 Fuc.sub.3 nLc.sub.8.

Abstract: Novel monoclonal antibodies capable of distinguishing between cyclosporins, e.g. Cyclosporine, and metabolites, e.g. Cyclosporins 17 and 18, are produced, e.g. starting from novel cyclosporins having an activated coupling group, e.g. activated carboxy group, e.g. (i) [(O-succinimidooxysuccinyl)-Thr].sup.2 -Cyclosporine and (ii) [(N-.epsilon.-succinimidooxysuccinyl)-(D)Lys].sup.8 -Cyclosporine. Cyclosporin starting materials required for the production of cyclosporins of type (ii), e.g. [(D)Lys].sup.8 -Cyclosporine are also new and additionally have utility in the preparation of novel labelled cyclosporin derivatives, as well as antibodies and antisera generally. Also claimed are novel antigenic conjugates and hybridoma cell lines used in the production of antibodies and antisera as aforesaid as well as assay kits comprising novel antisera, antibodies and/or labelled cyclosporins as aforesaid.

Abstract: Monoclonal antibodies to prostatic cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies show specificity for a non-soluble, membrane associated, organ specific antigenic determinant limited in its distribution to normal and neoplastic, human prostate epithelial cells. The monoclonal antibodies, specifically 7E11-C5 monoclonal antibodies, may be suitable for diagnostic uses.

Abstract: A hybridoma producing a monoclonal antibody specific for free N-acetylneuraminic acid or beta glycoconjugates thereof, is herein disclosed. The hybridoma can be generated by fusing (i) B cells of lymphocytes obtained by immunizing an animal with an N-acetylneuraminic acid or a beta-glycoconjugate thereof, and (ii) myeloma cells.

Abstract: Monoclonal antibodies having a specificity for protease nexin-1 are described. Preferably an antibody has specificity to the reactive protease-binding site. The antibody is used in the affinity purification of PN-1 to produce large quantities of substantially pure PN-1, free of other biologically active molecules. Over a 2000-fold purification of a crude preparation of PN-1 may be obtained. The affinity-purified PN-1 is suitable for use in pharmacological preparations used in the treatment of neurological disease associated with serine protease-mediated inhibition of regenerative processes.

Abstract: The present invention relates to a monoclonal antibody which specifically binds to a peptide having amino acid sequence (I) described below or having in part at least continuous 4 amino acid sequences of the amino acid sequence (I), and also to a process for producing a monoclonal antibody capable of specifically binding to the peptide represented by the following amino acid sequence:H-Y-Leu-Gly-Arg-X-Asp-Gly-Ser-Glu-OH (I)wherein X represents Glu or Gln and Y represents Trp or Arg.

Abstract: The present invention relates to methods of producing an antibody highly specific to a low-molecular weight substance such as amino acids, peptides, amines, steroids, etc. The invention also relates to a process for producing the same by forming a complex of the substance with colloidal metal particles and sensitizing a mammal with the complex. The antibody can be in the form of an antiserum containing the antibody. Since the antibody has a high specificity to the intended low-molecular weight substance, it is useful as a reagent for various immunohistochemical methods and immunoassays.

Abstract: Antigenic epitopes associated with the extracellular segment of the domain which anchors immunoglobulins to the B cell membrane are disclosed. For IgE, the epitopes are present on IgE-bearing B cells but not basophils or the secreted, soluble form of IgE. The epitope can be exploited for diagnosis.

Abstract: Monoclonal antibody (mAb) 1E10.1 immunologically distinguishing human bone from human liver alkaline phosphatase isoenzymes by specific binding to the former and not the latter is developed. mAb 1B12 is useful as a positive control as it reacts with human bone and liver ALP. Also developed is mAb 2B11 (2B11.1) which is useful as a positive control in rat ALP systems as it reacts with rat bone, liver, kidney and cartilage ALP.

Abstract: Anti-human pulmonary adenocarcinoma monoclonal antibody ALC-864 which belongs to the class IgG.sub.1, reacts with human pulmonary adenocarcinoma cells but not with normal human cells, recognizes proteins as antigens, and is useful for the identification of pulmonary adenocarcinoma selectively from among normal cells and for distinguishing this cancer from among other types of cancer.

Abstract: A 155 kDa phagocyte-specific antigen which is expressed on human monocytes, monocyte-derived macrophages and peritoneal macrophages, but is not expressed on human granulocytes, lymphocytes and platelets is described.

Abstract: Monoclonal antibody NKY13 recognizing sugar chains of mucin-type glycoproteins secreted by cancer cells, for example, the following sugar chains, and hydridoma producing it: ##STR1## The monoclonal antibody NKY13 renders it possible to make highly sensitive judgements in the serodiagnosis of such cancers as colon cancer, stomach cancer and pancreas cancer.

Abstract: Monoclonal antibodies produced by a family of murine hybrid cell lines are cross-reactive with both toxin A and toxin B of Clostridium difficile. The monoclonal antibodies are useful in an immunoassay for toxin A and toxin B of C. difficile, a casual agent of antibiotic-associated pseudomembranous colitis in humans and animals.

Abstract: The invention relates to Tetranectin, a new protein isolated from blood. Its structure comprises four polypeptide chains having the formula shown in the attached drawing.Tetranectin plays a role in the hemostatic system and, therefore, may be used as an agent for regulation of hemostasis.Further, the invention relates to a process for preparing Tetranectin in which Tetranectin is isolated, e.g. from blood or blood fractions, cells or genetically engineered organisms.Finally the invention relates to antiserum or antibodies against Tetranectin, to immunological detection and assay methods wherein said antiserum or antibodies are used as immunological reagent, and to pharmaceutical compositions containing Tetranectin or antibodies against Tetranectin.

Abstract: Monoclonal antibodies Pes-1, Pes-2, Pes-3 and Pes-4 which are respectively produced by hybridomas hPro-1.10G (FERM BP-1986), hPro-4.10H (FERM BP-2634), hPro-5.10F and hPro-1.5F specifically bind to the surface of human prostatic epithelial cells. They do not bind to any of many other normal or tumor tissues. The monoclonal antibodies are prepared by immunizing an animal with pieces of epithelial tissue from human prostate as an antigen, fusing antibody-producing cells of the animal with myeloma cells, selecting a hybridoma which produces the antibody, cultivating the hybridoma and recovering the antibody. The monoclonal antibodies have utility for histological examination for metastatic nests in prostatic cancer, preoperative examination in prostatic cancer, diagnosis of prostatic cancer.

Abstract: Monoclonal antibody to Treponema denticola JD-1 and Treponema species 10A and a continuous cell line for its production is disclosed. These antibodies are particularly useful in immunoassays for detecting the presence of these microorganisms in the oral cavity.